Market Overview
According to IMARC Group's latest research publication, "Dry Eye Syndrome Market Size, Share, Trends, and Forecast by Disease Type, Drug Type, Product, Distribution Channel, and Region, 2026-2034", the global dry eye syndrome market size reached USD 5.2 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 8.0 Billion by 2034, exhibiting a growth rate (CAGR) of 4.83% during 2026-2034.
This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.
How Digital Screen Exposure is Reshaping the Future of Dry Eye Syndrome Market
-
Office workers spend an average of 6.5 hours each day in front of computer screens or laptops, excluding time spent on mobile devices at work.
-
Americans average nearly 11 hours of screen time per day, with the majority occurring during work hours.
-
The WHO estimates that approximately 90% of the global population is exposed to polluted air, exacerbating dry eye symptoms.
-
In June 2024, Oculis Holding AG reported positive topline results from its Phase 2b RELIEF trial of licaminlimab, an anti-TNFα biologic eye drop for dry eye disease.
-
In May 2024, Nordic Pharma, Inc. launched LACRIFILL Canalicular Gel in the United States, an FDA-cleared treatment for dry eye disease.
Grab a sample copy of this report: https://www.imarcgroup.com/dry-eye-syndrome-market/requestsample
Key Trends in the Dry Eye Syndrome Market
-
Rising Geriatric Population: The increasing geriatric population is an important driver for the market growth around the world. Dry eye syndrome is more common in the geriatric population due to the natural aging process, which impacts the eye's ability to produce sufficient tears. Furthermore, countries across the globe are experiencing an increase in life expectancy, which, in turn, is increasing the geriatric population. This shift has a direct impact on the prevalence of age-related medical conditions, including dry eye syndrome. Besides this, geriatric adults are more susceptible to chronic health illnesses, and medications used for these conditions often have side effects that exacerbate dry eye symptoms. As a result, healthcare systems are facing an increased demand for both diagnostic services and treatments for dry eye syndrome, such as lubricating eye drops, prescription medications, and specialized eye care services.
-
Increasing Screen Time: The rising screen time among various age groups is a substantial factor fueling the market growth. Office workers spend an average of 6.5 hours each day in front of computer screens or laptops, excluding time spent on mobile devices at work. Additionally, Americans average nearly 11 hours of screen time per day, with the majority occurring during work hours. Modern lifestyles are dependent on digital screens, such as smartphones, tablets, and computer monitors. Furthermore, the emerging remote working culture is extending the exposure of employees to digital screens, which decreases the frequency of blinking, causing dryness in the eyes. Besides this, several studies are indicating a strong association between heightened screen time and symptoms of dry eye syndrome among young adults. Therefore, the escalating need for treatments targeting digital eye strain-induced dry eye is contributing to increased consumer spending on over the counter (OTC) artificial tears, prescription treatments, and devices designed to reduce digital eye strain.
-
Growing Environmental Pollution: Environmental factors also play an important role in the expansion of the dry eye syndrome market. The WHO estimates that approximately 90% of the global population is exposed to polluted air. Polluted air and extreme weather conditions in rapidly industrializing regions are exacerbating the symptoms of dry eye syndrome. In line with this, air pollution particles cause irritation and are often toxic to the eye's delicate tissues, thereby inducing or aggravating dry eye symptoms. Furthermore, various indoor pollutants, including volatile organic compounds (VOCs) emitted from cleaning products, paints, and other household items, reduce indoor air quality and lead to eye irritation and dryness. Besides this, allergic reactions from polluted environments can trigger dry eye symptoms in individuals who are susceptible to allergies. Moreover, environmental pollution contributes to climate change, which can alter weather patterns and humidity levels. These changes significantly affect tear evaporation rates and exacerbate dry eye symptoms, especially in arid regions.
-
Advancements in Therapeutic Solutions: The market is expanding because of advancements in therapeutic solutions and diagnostic tools, such as novel prescription eye drops, artificial tears, and medical gadgets. Early identification and treatment are also being encouraged by rising healthcare costs and increasing awareness about eye health. In June 2024, Oculis Holding AG reported positive topline results from its Phase 2b RELIEF trial of licaminlimab, an anti-TNFα biologic eye drop for dry eye disease (DED). The study evaluated 122 patients, including a subset with a TNFR1-related genotype, over six weeks. The results demonstrated efficacy and safety, supporting licaminlimab as a potential treatment for DED.
-
Increasing Awareness About Eye Health: Early diagnosis and treatment are also being encouraged by expanding education programs and awareness efforts run by groups like the American Optometric Association (AOA). The adoption of cutting-edge diagnostic and treatment solutions is facilitated by the United States' strong healthcare system and widespread insurance coverage for eye care. The IMARC Group's report shows that the United States dry eye syndrome market is expected to reach US$ 3.8 Billion.
Growth Factors in the Dry Eye Syndrome Market
-
Increasing Incidence of Eye-Related Illnesses: The increasing incidence of eye-related illnesses, especially among the elderly population, which is more vulnerable to long-term ailments like dry eyes, represents one of the key factors supporting the growth of the market. Dry eye symptoms are becoming more common in several age groups as a result of increased screen time brought on by the widespread use of digital gadgets and environmental variables like pollution and arid regions.
-
Growing Consumer Healthcare Spending: The market is expanding because of advancements in therapeutic solutions and diagnostic tools. Early identification and treatment are also being encouraged by rising healthcare costs and increasing awareness about eye health. The increasing consumer healthcare spending supports the adoption of advanced diagnostic and treatment solutions.
-
Robust Healthcare Infrastructure: The adoption of cutting-edge diagnostic and treatment solutions is facilitated by the United States' strong healthcare system and widespread insurance coverage for eye care. Furthermore, North America has a robust network of hospitals and clinics that specialize in ophthalmology, which facilitates prompt diagnosis and treatment.
-
Presence of Leading Pharmaceutical Companies: The market is further driven by the existence of top pharmaceutical businesses and continuous advancements in eye care goods like sophisticated treatments and diagnostic instruments. Key players, such as Allergan and Novartis, are pushing ahead with the development of new therapies, including the latter's FDA-approved CEQUA, which is bolstering the growth of the market.
-
Rising Awareness About Eye Health: A significant part is also played by high healthcare costs, extensive insurance coverage, and heightened public awareness about eye health. Awareness campaigns, such as those promoted by the European Dry Eye Society, call for early diagnosis and management. New diagnostic technologies, including the TearLab Osmolarity System, are being adopted for more precise assessments.
Leading Companies Operating in the Global Dry Eye Syndrome Industry
-
Akorn Operating Company LLC
-
Alimera Science
-
Allergan plc.
-
Auven Therapeutics
-
Bausch + Lomb Incorporated
-
GlaxoSmithKline plc
-
Nicox S.A.
-
Novartis AG
-
Otsuka Holdings Co., Ltd.
-
Santen Pharmaceutical Co., Ltd.
Dry Eye Syndrome Market Report Segmentation
Breakup By Disease Type
-
Evaporative Dry Eye Syndrome
-
Aqueous Dry Eye Syndrome
Evaporative dry eye syndrome leads the market with around 75.5% of market share. Due to its complex character and high incidence, evaporative dry eye syndrome (EDES) is the most common illness category. This illness is made worse by modern lifestyle choices like extended use of digital screens, increasing reliance on air conditioning (AC), and exposure to contaminants in the environment. Owing to physiological changes in gland function and tear production, the elderly population, a major demographic for eye disorders, is particularly vulnerable to EDES. Because the condition is chronic, it must be managed on time, which is driving the demand for therapeutic options like anti-inflammatory drugs, artificial tears, and cutting-edge therapies like thermal pulsation devices. Additionally, rising diagnosis rates owing to advancements in diagnostic technology and greater awareness about eye health are making EDES a common eye syndrome worldwide.
Breakup By Drug Type
-
Anti-inflammatory Drugs
-
Lubricant Eye Drops
-
Autologous Serum Eye Drops
Anti-inflammatory drugs lead the market with around 53.3% of market share. As inflammation is a major contributing element to many eye problems, anti-inflammatory medications are the most common type of drugs in the market. Inflammation frequently aggravates symptoms and prevents recovery in conditions, such as dry eye syndrome, uveitis, and allergic conjunctivitis. These medications, which include cyclosporine, corticosteroids, and nonsteroidal anti-inflammatory medicines (NSAIDs), provide quick symptom relief by efficiently reducing discomfort, swelling, and redness. The need for anti-inflammatory therapy is increasing due to the rising incidence of chronic eye problems associated with age, extended screen time, and environmental irritants. Furthermore, improvements in medication formulations like sustained-release and preservative-free choices, are improving therapeutic results and patient compliance. Their market share is further supported by the growing awareness among the masses about eye health issues and the accessibility of both prescription and over-the-counter (OTC) anti-inflammatory medications.
Breakup By Product
-
Liquid Drops
-
Gel
-
Liquid Wipes
-
Eye Ointment
-
Others
Liquid drops lead the market with around 59.3% of market share. Because of the versatility, effectiveness, and ease of use of liquid drops for a wide range of eye problems, they are the most popular product category in the eye syndrome market. Patients prefer liquid drops as a non-invasive solution for instant symptom alleviation, especially for dryness, irritation, and inflammation. They provide a range of products, such as antibiotic drops for infections, antihistamines for allergies, and artificial tears for dry eye condition. The need for these treatments is growing because of the rising incidence of diseases like dry eye syndrome, which are caused by environmental factors, digital screen usage, and aging populations. Furthermore, formulation developments including multi-dose vials and preservative-free alternatives are improving use and safety. Their dominance is further reinforced by their accessibility and cost, both through prescription drugs and over-the-counter (OTC).
Breakup By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
Hospital pharmacies lead the market with around 56.3% of market share. Because they play a crucial role in delivering specialist eye care treatments and guaranteeing access to prescription pharmaceuticals, hospital pharmacies are the main distribution channel in the market for eye syndrome. They are the main source for recommended pharmaceuticals, such as antibiotics, anti-inflammatory drugs, and advanced therapies, as ophthalmologists frequently diagnose eye syndrome and develop treatment regimens for patients in hospital settings. These pharmacies have the benefit of providing quick access to necessary medications, particularly in circumstances that are urgent or severe. Hospital pharmacies are also reputable for upholding strict quality standards and providing a variety of specialty goods, such as compounded formulas for difficult situations. The dependence on hospital pharmacists is further fueled by the rising incidence of chronic eye disorders and increasing hospitalizations for diagnostic and treatment operations.
Breakup By Region
-
North America (United States, Canada)
-
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
-
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
-
Latin America (Brazil, Mexico, Others)
-
Middle East and Africa
North America accounted for the largest market share of over 55.0%. Owing to its sophisticated healthcare system, high incidence of eye conditions, and substantial expenditure in R&D, North America dominates the market for eye syndrome. The prevalence of diseases like dry eye syndrome is increasing in the region due to aging population, widespread use of digital screens, and environmental factors like pollution and air conditioning (AC). Furthermore, North America has a robust network of hospitals and clinics that specialize in ophthalmology, which facilitates prompt diagnosis and treatment. The market is further driven by the existence of top pharmaceutical businesses and continuous advancements in eye care goods like sophisticated treatments and diagnostic instruments. A significant part is also played by high healthcare costs, extensive insurance coverage, and heightened public awareness about eye health.
In 2025, the dry eye syndrome market in the United States accounts for over 89% of the North American market share. It is driven by the high prevalence of dry eye disease, advanced healthcare infrastructure, and considerable R&D investment. Pharmaceutical innovations, including FDA-approved treatments like Xiidra and Restasis, are propelling the market growth. Telemedicine platforms are increasingly used for diagnosis and treatment of the condition. Further government initiatives, such as the National Eye Institute funding for research related to vision further fortify this market. Key players, such as Allergan and Novartis, are pushing ahead with the development of new therapies, including the latter's FDA-approved CEQUA, which is bolstering the growth of the market.
Recent News and Developments in Dry Eye Syndrome Market
-
June 2024: Oculis Holding AG reported positive topline results from its Phase 2b RELIEF trial of licaminlimab, an anti-TNFα biologic eye drop for dry eye disease (DED). The study evaluated 122 patients, including a subset with a TNFR1-related genotype, over six weeks. The results demonstrated efficacy and safety, supporting licaminlimab as a potential treatment for DED.
-
May 2024: Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel in the United States. This is a FDA-cleared treatment for dry eye disease and uses a cross-linked hyaluronic acid derivative to temporarily block tear drainage by occluding the canalicular system.
Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.
About Us
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel NoD) +91 120 433 0800
United States: +1-201971-6302
Comments (0)